Evaluation of candidates for mechanical circulatory support devices
===================================================================

In advanced heart failure (HF), the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) proposed seven clinical profiles (and modifiers) for a convenient, easy classification of disease status, risk of implantation of mechanical circulatory support devices (MCSDs) and adequate time for intervention ([Chart 1](#t1){ref-type="table"}).^[@r1]^

###### 

Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profiles

  Profile   Description                                   Hemodynamic status                                                                                                                Time frame for definitive intervention
  --------- --------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------
  1         Critical cardiogenic shock                    Persistent hypotension despite the use of inotropes and intra-aortic balloon pumps, associated with organic dysfunction           Hours
  2         Progressive decline, but inotrope dependent   Deterioration of renal and hepatic function, nutritional status and lactate levels, despite use of inotropes in optimized doses   Days
  3         Stable but inotrope dependent                 Clinical stability on continuous inotropic therapy, and history of failure to wean from it                                        Weeks - months
  4         Frequent hospitalization                      Signs of water retention, symptoms at rest and frequent admissions to emergency departments                                       Weeks - months
  5         At home, exertion intolerant                  Intolerant to activity, comfortable at rest despite water retention                                                               Intervention emergency depends on nutritional status and organic dysfunction severity
  6         Exertion limited                              Moderate limitation to activity; absence of signs of hypervolemia                                                                 Intervention emergency depends on nutritional status and organic dysfunction severity
  7         NYHA III                                      Hemodynamic stability and absence of hypervolemia                                                                                 Intervention is not indicated

NYHA: New York Heart Association.

One of the main determinant factors for a successful MCSD implantation is patient eligibility. Correct selection of patients involves -- (1) patients with advanced HF to which the risk of MCSD implantation surpasses mortality risk for current disease (making it a beneficial intervention); (2) patients with moderately advanced HF, i.e., implantation of MCSD would not increase patient's morbidity and mortality due to increased complication rate; (3) no contraindications for MCSD implantation.^[@r2],[@r3]^

Perioperative renal failure, pre-existing right HF, liver dysfunction, mechanical ventilation in the pre-operative period, low weight or overweight and reoperation have been related to worse clinical outcomes after MCSD implantation.^[@r3]-[@r5]^

The main scores for risk prediction in MCSD implantation are described in [Chart 2](#t2){ref-type="table"}.

###### 

Risk predictors for mechanical circulatory support device implantation

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Risk score for destination therapy^[@r6]^      Risk score for bridge/destination therapy (HMII score)^[@r7]^   Pre-operative risk score^[@r8]^           Pre-operative risk score^[@r9]^
  ---------------------------------------------- --------------------------------------------------------------- ----------------------------------------- -------------------------------------------
  Risk of 90-day in-hospital mortality\          Ninety-day mortality\                                           Mortality risk after MCSD implantation\   Mortality risk after MCSD implantation\
  (pulsatile flow)                               (continuous flow)                                               (mean of 84 days)                         (mean of 100 days)

  Platelets \< 148.000/µL\                       Age (for 10 years)\                                             Urine flow \< 30 mL/hour\                 Respiratory failure /sepsis OR: 11,2
  OR: 7.7                                        OR: 1.32                                                        RR: 3.9                                   

  Albumin \< 3.3 mg/dL\                          Albumin\                                                        CVP \> 16 mmHg\                           Right heart failure\
  OR: 5.7                                        OR: 0.49                                                        RR: 3.1                                   OR: 3.2

  INR \> 1,1\                                    Creatinine\                                                     Mechanical ventilation\                   Age \> 65 years\
  OR: 5.4                                        OR: 2.1                                                         RR: 3                                     OR: 3.01

  Use of vasodilator\                            INR\                                                            Prothrombin time \> 16 seconds\           Postcardiotomy acute ventricular failure\
  OR: 5.2                                        OR: 3.11                                                        RR: 2.4                                   OR: 1.8

  Pulmonary artery medium pressure \< 25 mmHg\   Center volume \< 15 implants\                                   Reoperation\                              Acute myocardial infarction\
  OR: 4.1                                        OR: 2.24                                                        RR: 1.8                                   OR: 1.7

  ALT \> 45 U/mL\                                                                                                Leucocytes \> 15.000\                      
  OR: 2.6                                                                                                        RR: 1.1                                   

  Hematocrit \< 34%\                                                                                             Temperature \> 101.5 F\                    
  OR: 3,0                                                                                                        RR: 0                                     

  BUN \> 51 U/dL\                                                                                                                                           
  OR: 2.9                                                                                                                                                  

  Intravenous inotropic support\                                                                                                                            
  OR: 2.9                                                                                                                                                  
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

HMII: HeartmateII; OR: odds ratio; RR: relative risk; CVP: central venous pressure; INR: international normalized ratio; ALT: alanine transaminase; BUN: Blood Urea Nitrogen. MCSD: mechanical circulatory support device

Echocardiography
================

Evaluation of patients candidates for MCDS should include a transthoracic echocardiogram (TEE) complemented by a transesophageal echocardiography (TEE).

The effects of MCDS on right ventricular function depend on the balance between the benefits of decompression of the left chambers (reduction of the left ventricular afterload) and greater volumetric load to the right atrium (RA; increase of the right ventricular preload). Decompression of left chambers also cause changes in the geometry of the right chambers, such as leftward shift of interatrial (IAS) and interventricular septum (IVS), structural changes of tricuspid annulus, which can aggravate a pre-existing tricuspid insufficiency (TI) and right ventricular overload.^[@r10]^

Considering that right ventricular cardiac output determines left ventricular preload, a significant reduction in right ventricular function results in decreased output by the MCSD. It is estimated that approximately 30% of patients with left ventricular assist device develop limiting right ventricular dysfunction. For these reasons, a careful evaluation of right ventricular function is mandatory before MCDS implantation. In the presence of moderate-to-severe dysfunction, the requirement of a permanent biventricular support cannot be ruled out.^[@r11]^

In the assessment of right ventricular function before MCSD implantation, it is recommended the measurement of the right ventricle, as well as a semiquantitative assessment of right ventricular longitudinal and radial contractility combined with quantitative parameters, including fractional area change (FAC; FAC \< 20% are associated with increased risk of right ventricular dysfunction after MCSD implantation),^[@r12]^ tricuspid annular plane systolic excursion (TAPSE) determined by M mode, peak systolic velocity of lateral tricuspid ring, measured by tissue Doppler (s'), and right ventricular performance index.^[@r13],[@r14]^

Predictors of right ventricular dysfunction before mechanical circulatory support device implantation
-----------------------------------------------------------------------------------------------------

Right ventricular dysfunction is multifactorial and includes an increase in preload, ventricular ischemia and mechanical interdependence of ventricular geometry. It is one of the most severe complications of left ventricular assist device, observed in up to 30% of cases and associated with a six-fold increase in morbidity and mortality (increased risk in up to 67%).^[@r11],[@r15]^

Risk factors and the main risk score for right ventricular dysfunction after MCSD implantation are described in [Charts 3](#t3){ref-type="table"} and [4](#t4){ref-type="table"}.

###### 

Risk factors for right ventricular dysfunction after mechanical circulatory support device implantation (MCSD)^[@r16]^

  Indication of MCDS                                                        Destination therapy
  ------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Sex                                                                       Female
  Pre-implantation support                                                  Intra-aortic balloon pump and vasopressor requirement
  Organic dysfunctions                                                      Respiratory: invasive ventilatory support
  Hepatic: ALT ≥ 80 UI/L. bilirubin \> 2.0 mg/dL                            
  Renal: serum creatinine ≥ 2.3 g/dLHistory of kidney replacement therapy   
  Nutritional: albumin ≤ 3.0 g/dL                                           
  Coagulation: platelets \< 120,000                                         
  Others: increased BNP. PCR. Procalcitonin                                 
  Right ventricular dysfunction                                             Right ventricular diastolic diameter \> 35 mm. FAC \< 30%. Right atrium \> 50 mm
  Hemodynamic measures                                                      CVP ≥ 15 mmHg or CVP/PCP ≥ 0.63. right ventricular work index ≤ 300 mmHg mL/m^2^; low pulmonary artery pressures, low cardiac index or increased pulmonary vascular resistance
  Others                                                                    Non-ischemic cardiomyopathy, reoperation, important TI, history of PTE

ALT: alanine transaminase; BNP: brain natriuretic peptide; CRP: C-reactive protein; FAC: fractional area change; CVP: central venous pressure; PCP pulmonary capillary pressure; TI: tricuspid insufficiency; PTE: pulmonary thromboembolism

###### 

Main risk scores for right ventricular failure after left ventricular mechanical circulatory support device implantation

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Score                                                                           Variables                                                           Prediction
  ------------------------------------------------------------------------------- ------------------------------------------------------------------- --------------------------------------------------------------
  University of Michigan, RV Failure Risk Score, Matthews et al.^[@r17]^          Vasopressor requirement: 4 points\                                  Likelihood of right ventricular failure\
                                                                                  TGP ≥ 80 IU/L: 2 points\                                            • ≥ 5.5 points: 7.6\
                                                                                  Bilirubin ≥ 2.0 mg/dL: 2.5 points\                                  • 4.0-5.0 points: 2.8\
                                                                                  Creatinine ≥ 2.3 mg/dL or hemodialysis: 3 points                    • ≤ 3.0 points: 0.49

  Kormos et al.^[@r18]^                                                           Pre-operative predictors for early left ventricular dysfunction:\   One-year survival:\
                                                                                  CVP/PCP \> 0.63\                                                    • Absent right ventricular dysfunction: 78%\
                                                                                  Ventilatory support\                                                • Early right ventricular dysfunction: 59% (p\< 0.001)
                                                                                  BUN \> 39 mg/dL                                                     

  University of Pennsylvania, RV Failure Risk Score, Fitzpatrick et al.^[@r19]^   Cardiac index ≤ 2.2 L/min/m^2^: 18 points\                          \< 30: 96%, isolated left ventricular assist device\
                                                                                  SVRI ≤ 0.25 mmHg-L/m^2^: 18 points\                                 ≥ 65 points: 11%, isolated left ventricular assist device
                                                                                  Important right ventricular dysfunction: 17 points\                 
                                                                                  Serum creatinine ≥ 1.9 mg/dL: 17 points\                            
                                                                                  Previous cardiac surgery: 16 points\                                
                                                                                  Systolic arterial pressure ≤ 96 mmHg: 13 points                     

  CRITT score^[@r20]^                                                             CVP \> 15 mmHg: 1 point\                                            1-2 points: low risk for right ventricular dysfunction\
                                                                                  Severe right ventricular dysfunction: 1 point\                      2-3 points: moderate risk for right ventricular dysfunction\
                                                                                  Pre-operative mechanical ventilation: 1 point\                      4-5 points: high risk for right ventricular dysfunction
                                                                                  Important tricuspid insufficiency: 1 point\                         
                                                                                  Tachycardia (\> 100 bpm) = 1 point                                  
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ALT: alanine transaminase; CVP: central venous pressure; PCP pulmonary capillary pressure; BUN: Blood Urea Nitrogen; SVRI: systemic vascular resistance index

Implantation of a MCSD in the left ventricle should be performed with caution in patients with important right ventricular dilation, moderate-to-severe tricuspid insufficiency, tricuspid valve annulus \> 45 mm and CVP \> 15 mmHg. By this means, hemodynamic variables directly reflect a preload or afterload increase and right ventricular contractility reductions, whereas venous congestion and organ hypoperfusion, consequence of right ventricular dysfunction, indicate hepatic and renal dysfunctions^[@r15],[@r21]^

Positive hemodynamic indicators of adequate right ventricular function that might reduce the risk of post-MCSD implantation dysfunction are: CVP ≤ 8 mmHg; PCP ≤ 18 mmHg; CVP/PCP ≤ 0,66; pulmonary vascular resistance (PVR) \< 2 wood units and right ventricular work index ≥ 400 mL/m^2^.

Temporary devices
=================

Selection of strategies for temporary mechanical circulatory support devices
----------------------------------------------------------------------------

Temporary MCSD can be used for hemodynamic and clinical stability restoration, aiming at improvement of cardiac function and transplantation. Three strategies (which may be overlapped) can be defined:

**Bridge to decision:** should be considered in severely ill patients, who requires immediate hemodynamic support due to high risk of cardiac failure. It may occur in different situations -- lack of neurological recovery, multiple organ failure, hemodynamic stabilization and requirement of other devices -- in which the final strategy of therapy cannot be established during device implantation (e.g. after cardiorespiratory arrest).^[@r22]^**Bridge to recovery:** situation in which support device is removed for ventricular function recovery, such as ventricular dysfunction following acute myocardial infarction, Takotsubo cardiomyopathy and myocarditis.^[@r23]^**Bridge to transplantation:** situations in which the patient is in progressive severity and heart transplantation cannot be performed in a short term. Support devices may provide hemodynamic support and clinical stability until transplantation is performed.

Types of temporary mechanical circulatory support devices
---------------------------------------------------------

Main characteristics of temporary MCSDs available in Brazil are described in [Chart 5](#t5){ref-type="table"}.^[@r24]^

###### 

Temporary mechanical circulatory support devices available in Brazil

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics       Intra-aortic balloon                  ECMO                                                                                                                       TandemHeart™                                                     Impella 2.5®\                                      CentriMag®                                                              EXCOR®
                                                                                                                                                                                                                                                          Impella CP®\                                                                                                               
                                                                                                                                                                                                                                                          Impella 5.0®                                                                                                               
  --------------------- ------------------------------------- -------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------- -------------------------------------------------- ----------------------------------------------------------------------- ----------------------------------------------------
  Mechanism             Pneumatic                             Centrifugal                                                                                                                Centrifugal                                                      Axial                                              Centrifugal                                                             Pulsatile

  Access                Percutaneous                          Percutaneous / thoracotomy                                                                                                 Percutaneous                                                     Percutaneous\                                      Thoracotomy                                                             Thoracotomy
                                                                                                                                                                                                                                                          Percutaneous\                                                                                                              
                                                                                                                                                                                                                                                          Dissection                                                                                                                 

  Cannulation           7-9 F                                 18-21 F Inflow\                                                                                                            21 F Inflow\                                                     12 F\                                              24-34 F                                                                 27-48 F\
                                                              15-22 F Outflow                                                                                                            15-17 F Outflow                                                  14 F\                                                                                                                      Inflow\
                                                                                                                                                                                                                                                          21 F                                                                                                                       36-48 F Outflow

  Insertion technique   Descending aorta via femoral artery   Percutaneous:\                                                                                                             Inflow: left atrium via femoral vein and transseptal puncture\   Insertion into left ventricle via femoral artery   ACM-E:\                                                                 ACM-E:\
                                                              - Inflow: right atrium via femoral or jugular vein\                                                                        Outflow: femoral artery                                                                                             - Inflow: left ventricle (via left atrium or apex of left ventricle)\   - Inflow: left ventricle (apex of left ventricle)\
                                                              - Outflow: descending aorta via femoral artery\                                                                                                                                                                                                - Outflow: ascending aorta\                                             - Outflow: ascending aorta\
                                                              Thoracotomy:\                                                                                                                                                                                                                                  ACM-D:- Inflow: right atrium\                                           ACM-D:\
                                                              - Inflow: right atrium\                                                                                                                                                                                                                        - Outflow: pulmonary artery                                             - Inflow: right atrium\
                                                              - Outflow: pulmonary artery (left mechanical circulatory assist device) or ascending aorta (biventricular assist device)                                                                                                                                                                                               - Outflow: pulmonary artery

  Hemodynamic support   0.5 L/min                             \> 4.5 L/min                                                                                                               4 L/min                                                          2.5 L/min\                                         Up to 8-10 L/min                                                        Up to 8 L/min
                                                                                                                                                                                                                                                          3.7 L/min\                                                                                                                 
                                                                                                                                                                                                                                                          5.0 L/min                                                                                                                  
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ECMO: Extracorporeal membrane oxygenation

### Indications and contraindications

Although temporary MCSDs are primarily indicated for patients INTERMACS levels 1 and 2, INTERMACS level 3 patients, dependent of high doses of inotropes or at high risk of hemodynamic instability may also be considered eligible.

Contraindications for temporary MCDS include limiting clinical situations that require individualized approach and involvement of other professionals (e.g. oncologist for establishment of cancer prognosis).

### Intra-aortic balloon pump (IABP)

The mechanism of action of the IABP is aortic counterpulsation, which increases diastolic pressure at aortic root, promoting an increase in coronary perfusion, afterload reduction, and consequently an increment in cardiac output by 15%.

Although IABP is still used in the clinical practice especially in younger patients with less severe cardiogenic shock, the efficacy of the method should be carefully evaluated based on improvement of objective parameters of tissue microperfusion. Lack of improvement of these variables in a short time period (hours) justifies the selection of more invasive devices.

###### 

Recommendations for intra-aortic balloon pump implantation

  Recommendation                                                         Class   Evidence level
  ---------------------------------------------------------------------- ------- ----------------
  Post-AMI cardiogenic shock                                             IIa     B
  Post-AMI mechanical complication with cardiogenic shock                IIa     C
  Refractory angina after standard therapy for acute coronary syndrome   IIa     C
  Cardiogenic shock in ischemic / non-ischemic chronic cardiomyopathy    IIa     C
  Intervention support for patients at high cardiac risk                 IIb     C

AMI: acute myocardial infarction

Percutaneous circulatory devices
--------------------------------

### Definition and benefits

Percutaneous circulatory devices enable active support without requiring a synchronism with the cardiac cycle. The main benefits are maintenance of tissue perfusion, improvement of coronary perfusion, and reduction of myocardial oxygen consumption, filling pressures and ventricular wall stress, providing a circulatory support in cardiogenic shock.^[@r25],[@r26]^

###### 

Recommendations for percutaneous circulatory support device implantation

  Recommendation                                               Class   Evidence level
  ------------------------------------------------------------ ------- ----------------
  Post-AMI cardiogenic shock                                   IIa     C
  Support for interventions in patients at high cardiac risk   IIb     C

AMI: acute myocardial infarction

Types of percutaneous circulatory devices
-----------------------------------------

### Impella^®^

Impella device is composed of a continuous axial flow pump, that aspirates blood directly from the left ventricle and directs it to the aorta (works in series with left ventricle). It allows the flow of 2.5 L/min (Impella® 2.5), 4.0 L/min (Impella® CP) or 5.0 L/min (Impella® 5.0). The model currently available in Brazil is Impella® CP.^[@r24],[@r27]^

### TandemHeart™

TandemHeart™ system is composed of a centrifugal extracorporeal pump, a femoral cannula, a transseptal cannula and a control console. It pumps blood from the left atrium through a transseptal cannula to the ileo-femoral arterial system. Both TandemHeart™ and the left ventricle work in parallel and contribute to aortic blood flow.^[@r24],[@r27]^

Extracorporeal membrane oxygenation
-----------------------------------

### Definition, types and benefits

Extracorporeal membrane oxygenation (ECMO) is an invasive temporary mechanical support that provides partial or total cardiopulmonary support for patients with cardiogenic shock and/or acute respiratory insufficiency. There are two types of ECMO -- venoarterial and venovenous. With quick installation technology, ECMO promotes rapid reversal of circulatory failure and/or anoxia.

###### 

Recommendations for extracorporeal membrane oxygenation implantation

  Recommendation                   Class   Level of evidence
  -------------------------------- ------- -------------------
  Bridge to decision or recovery   I       C
  Bridge to transplantation        IIa     C

Paracorporeal circulatory support
---------------------------------

### Definition, types and benefits

Paracorporeal circulatory support devices are surgically implanted pumps that promote hemodynamic support in individuals with refractory cardiogenic shock with high mortality risk.

A CentriMag® is a continuous flow, magnetically levitated centrifugal blood pump. It provides up to 10 L/minute of blood flow and low shear stress, promoting low thrombogenicity, moderate anticoagulation levels and minimum hemolysis during support.^[@r24]^

Berlin Heart EXCOR® is a pulsatile-flow pump that provides up to 8 L/min of blood flow, with batteries connected to a transport system, allowing an up to ten hours of patient's mobility.

###### 

Recommendations for implantation of paracorporeal circulatory pumps

  Recommendation                   Class   Level of evidence
  -------------------------------- ------- -------------------
  Bridge to decision or recovery   IIa     C
  Bridge to transplantation        IIa     C

Other conventional centrifugal pumps may be used with the same purpose.

Long term devices
-----------------

### Types of long-term mechanical circulatory support devices

Due to technological progress, advances in long-term MCSD models have occurred during the last years, regarding pumping system and flow type, enabling its reduction in size, greater efficiency and lower complication rates ([Figure 1](#f1){ref-type="fig"}).

Figure 1Progress of long-term mechanical circulatory support devices.

The long-term MCSDs available in Brazil are described in [Chart 6](#t6){ref-type="table"}.

###### 

Long-term mechanical circulatory support devices available in Brazil

  Name               Company        Type of pump       Type of support   Presence of bearing               Anvisa Approval
  ------------------ -------------- ------------------ ----------------- --------------------------------- -----------------
   HeartMate II^®^   Thoratec       Axial flow         Left              Yes                               Yes
  INCOR^®^           Berlin Heart   Axial flow         Left              No (electromagnetic levitation)   Yes
  HeartWare^®^       HeartWare      Centrifugal flow   Left              No (electromagnetic levitation)   Yes

Anvisa: Agência Nacional de Vigilância Sanitária (The Brazilian Health Regulatory Agency); NA: not applicable

### Indications and contraindications

In making decision process for long-term MCSDs, some important factors should be considered. In case of bridge to transplantation, transplant waiting time should be taken into account; for waiting time shorter than 30 days, there would be a low benefit-cost ratio. Also, the use of these devices in INTERMACS level 2 patients may have unfavorable results.

###### 

Recommendations for long-term mechanical circulatory support devices as bridge to transplant

  Recommendation                                           Class       Level of evidence
  -------------------------------------------------------- ----------- -------------------
  Systolic heart failure - INTERMACS levels 2 and 3        Class IIa   C
  Systolic heart failure - INTERMACS level 4               Class IIb   C
  Systolic heart failure -INTERMACS levels 1, 5, 6 and 7   Class III   C

###### 

Recommendations for long-term mechanical circulatory support devices as destination therapy

  Recommendation                                    Class       Level of evidence
  ------------------------------------------------- ----------- -------------------
  Systolic heart failure -  INTERMACS 3             Class IIa   B
  Systolic heart failure - INTERMACS 2              C           
  Systolic heart failure - INTERMACS 4              Class IIb   C
  Systolic heart failure -  INTERMACS 1, 5, 6 e 7   Class III   C

###### 

Recommendations for long-term mechanical circulatory support devices as bridge to decision

  Recommendation                                     Class       Level of evidence
  -------------------------------------------------- ----------- -------------------
  Systolic heart failure - INTERMACS 2 and 3         Class IIa   C
  Systolic heart failure - INTERMACS 4               Class IIb   C
  Systolic heart failure - INTERMACS 1, 5, 6 and 7   Class III   C

Patients eligible for MCSD should be evaluated for the presence of factors that may contraindicate or negatively influence patients' survival after transplant. Main contraindications are listed in [Chart 7](#t7){ref-type="table"}.

###### 

Contraindications for long-term mechanical circulatory support devices

  ------------------------------------------------------------------------ --------------------------------------------------
  **Absolute**                                                             Coumarin intolerance
  Absence of trained caregivers                                            
  Severe psychiatric disorders or nonadherence to the staff instructions   
  Severe motor deficit or cognitive deficit related after stroke           
  Neoplastic disease with unfavorable prognosis                            
  Vascular malformation of the small bowel that predisposes to bleeding    
  Severe pulmonary obstructive disease                                     
  Severe hepatic dysfunction                                               
  Active infection                                                         
  Hematologic changes (platelets \< 50,000 mm^3^ and thrombophilia)        
  **Relative**                                                             Moderate-to-severe right ventricular dysfunction
  Dialytic therapy for renal failure                                       
  Difficult-to-control diabetes                                            
  Partial motor deficit after stroke                                       
  Severe malnutrition                                                      
  Significative peripheral artery disease                                  
  ------------------------------------------------------------------------ --------------------------------------------------

### Strategy for selection of long-term MCSDs

1.  **Bridge to decision:** long-term MCSDs may be indicated for patients with clinical conditions that contraindicate heart transplantation, but if modified, patients may become eligible for transplant (for example: pulmonary hypertension and curable cancers).

2.  **Bridge to transplant:** Situations in which MCSDs may provide hemodynamic support and clinical stability until heart transplant, in patients with progressive severity and when a short-term transplant is not possible.

3.  **Destination therapy:** Situations in which MCSDs may provide hemodynamic support and clinical stability in patients with refractory heart failure with contraindication for cardiac transplant, promoting higher survival and better quality of life as compared with clinical treatment with drugs.

### Optimization and management of right ventricular function

Right ventricular failure is still one of the main factors that affect patients' survival after MCSD implantation.^[@r28]^ Its diagnostic criteria are -- signs and symptoms for persistent right ventricular dysfunction; CVP \> 18 mmHg with cardiac index \< 2,0 L/min.m^2^ in the absence of ventricular arrhythmias or pneumothorax; requirement of ventricular support devices; or requirement for inhaled nitric oxide or inotropic therapy for more than one week after device implantation.^[@r29]^

Implantation of a MCSD increases cardiac output and consequently causes an increment in venous return to the right ventricle. To counteract this preload increase, right ventricular compliance should improve with reduction of its afterload (decrease in left ventricular filling pressure and pulmonary arterial pressure). However, leftward shift of IVS may occur in case of excessive left ventricular emptying.^[@r29]^

In addition to its contractility, optimization of right ventricular preload and afterload is crucial to prevent right ventricular failure in the perioperative period. CVP and systolic pulmonary pressure should be maintained lower than 16 mmHg and 65 mmHg, respectively. For maintenance of coronary perfusion, use of inotropes that cause pulmonary vasodilation (milrinone or dobutamine) and maintain adequate systemic pressure (adrenaline) is recommended. In addition, the use of specific pulmonary vasodilators, such as nitric oxide should be considered ([Figure 2](#f2){ref-type="fig"}).^[@r30]^

Figure 2Optimization and management of right ventricular function. MgSO~4~: magnesium sulfate; HR: heart rate; DC PM: dual-chamber pacemaker with right atrial and ventricular stimulation and sensitivity; LVAD: Left ventricular assist device; CVP: central venous pressure; CI: cardiac index; TTE: transthoracic echocardiogram; TEE: transesophageal echocardiography; RV: right ventricular; PVR: pulmonary vascular resistance; LV: left ventricular; SVR: systemic vascular resistance; RVAD: right ventricular assist device; mAP: mean arterial pressure.

### Complications after long-term MCSD implantation

The main complications related to long-term MCSD implantation are described in [Chart 8](#t8){ref-type="table"}.

###### 

Complications of long-term mechanical circulatory support devices (MCSDs)

  Bleeding                        Pericardial effusion    Respiratory insufficiency
  ------------------------------- ----------------------- -------------------------------------------
  Right ventricular dysfunction   Hypertension            Non-neurological arterial thromboembolism
  Neurological events             Arrhythmias             Venous thromboembolism
  Infections                      Myocardial infarction   Surgical wound dehiscence
  MCSD malfunction                Hepatic dysfunction     Psychiatric / behavioral change
  Hemolysis                       Renal dysfunction        

### Proposal of prioritization criteria for cardiac transplant in patients with MCSD

With increasing number of MCDSs, this document proposes a change in the prioritization criteria for patients in the cardiac transplant waiting list. These new criteria are described in [Chart 9](#t9){ref-type="table"}.

###### 

Proposal of prioritization criteria for cardiac transplant

  -----------------------------------------------------------------------------------------------------------------------
  Priority   Criterium
  ---------- ------------------------------------------------------------------------------------------------------------
  1          Cardiogenic shock in patients using short/medium-term paracorporeal MCDS (including intra-aortic balloon)\
             Long-term MCDS with complications and substitution of device is not possible

  2          Cardiogenic shock in patients using inotropes or vasopressors

  3          Stable long-term MCDS without complications

  4          Outpatient management of advanced heart failure
  -----------------------------------------------------------------------------------------------------------------------

MCDS: mechanical circulatory device support
